Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study

W. Canonica (Milan, Italy), J. Virchow (Rostock, Germany), D. Singh (Manchester, United Kingdom), M. Kots (Parma, Italy), F. Zuccaro (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), S. Petruzzelli (Parma, Italy)

Source: International Congress 2019 – Novel findings from asthma clinical trials
Session: Novel findings from asthma clinical trials
Session type: Oral Presentation
Number: 5339

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Canonica (Milan, Italy), J. Virchow (Rostock, Germany), D. Singh (Manchester, United Kingdom), M. Kots (Parma, Italy), F. Zuccaro (Parma, Italy), A. Vele (Parma, Italy), G. Georges (Parma, Italy), S. Petruzzelli (Parma, Italy). Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study. 5339

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: